• 1
    Wrigglesworth JM, Baum H. The biochemical functions of iron. In: JacobsA, WorwoodM, eds. Iron in Biochemistry and Medicine. Volume 1, Ed 1. London: Academic Press, 1980: 2986.
  • 2
    Testa U, Pelosi E, Peschle C. The transferrin receptor. Grit Rev Oncog 1993; 4: 24176.
  • 3
    Klausner RD, Ashwell G, Van Renswoude J, Harford JB, Bridges KR. Binding of apotransferrin to K562 cells: explanation of the transferrin cycle. Proc Natl Acad Sci U S A 1983; 80: 22632266.
  • 4
    Dautry-Varsat A, Ciechanover A, Lodish HF. pH and the recycling of transferrin during receptor-mediated endocytosis. Proc Natl Acad Sci US A 1983; 80: 22582262.
  • 5
    Krishnamurthy R, Harford JB, Roualt T, McLelland A, Ruddle FH, Klausner RD. Transcriptional regulation by iron of the gene for the transferrin receptor. Mol Cell Biol 1986; 6: 236240.
  • 6
    Bridges KR, Seligman PA. Disorders of iron metabolism. In: HandinRI, LuxSE, StosselTP, eds. Blood: Principles and Practice of Hematology. Volume 1. Ed 1. Philadelphia: Lippincott, 1995: 14331472.
  • 7
    Klausner RD, Van Renswoude J, Ashwell G, Kempf C, Schechter AN, Dean A, Bridges KR. Receptor-mediated endocytosis of transferrin in K562 cells. J Biol Chem 1983; 258: 47154724.
  • 8
    Aloj L, Lang L, Jagoda E, Neumann RD, Eckelman WC. The evaluation of human transferrin labeled with N-succinimidyl 4-[F-18] (fluoromethyl) benzoate. J Nucl Med 1996; 37: 14081412.
  • 9
    Aloj L, Carson RE, Lang L, Herscovitch P, Eckelman WC. Measurement of transferrin receptor kinetics in the liver using dynamic 3D-PET and [F-18] holo-transferrin [Abstract]. J Nucl Med 1996; 37 (Suppl): 203P.
  • 10
    Lang L, Eckelman WC. One-step synthesis of 18F labeled [18F]-N-succinimidyl 4-(fluoromethyl)benzoate for protein labeling. Appl Radiat Isot 1994; 45: 11551163.
  • 11
    Lang L, Eckelman WC. Labeling proteins at high specific activity using N-succinimidyl 4-[F-18] fluoromethyl benzoate. Appl Radiat Isot 1997; 48: 169173.
  • 12
    Carson RE. Mathematical modeling and compartmental analysis. In: HarbertJC, NeumannRD, EckelmanWC, eds. Nuclear Medicine: Diagnosis and Therapy. Volume 1. Ed 1. New York: Thieme, 1996: 167193.
  • 13
    Beck JV, Arnold KJ. Parameter Estimation in Engineering and Science. New York: Wiley, 1977.
  • 14
    Sasaki K, Zak O, Aisen P. Antisense suppression of transferrin receptor gene expression in a human hepatoma cell (HuH-7) line. Am J Hematol 1993; 42: 7480.
  • 15
    Thorstensen K, Romslo I. Uptake of iron from transferrin by isolated rat hepatocytes. A redox–mediated plasma membrane process? J Biol Chem 1988; 263: 88448850.
  • 16
    Bonkovsky HL. Iron and the liver. Am J Med Sci 1991; 301: 3243.
  • 17
    Richardson DR, Baker E. The uptake of iron and transferrin by the human malignant melanoma cell. Biochim Biophys Acta 1990; 1053: 112.
  • 18
    Ciechanover A, Schwartz AL, Dautry-Varsat A, Lodish HF. Kinetics of internalization and recycling of transferrin and the transferrin receptor in a human hepatoma cell line. Effect of lysosomotropic agents. J Biol Chem 1983; 258: 96819689.
  • 19
    Lemieux P, Page M. Sensitivity of multidrug-resist ant MCF-7 cells to a transferrin-doxorubicin conjugate. Anticancer Res 1993; 13: 397404.
  • 20
    Wellhoner HH, Neville DM Jr, Srinivasachar K, Erdmann G. Uptake and concentration of bioactive macromolecules by K562 cells via the transferrin cycle utilizing an acid-labile transferrin conjugate. J Biol Chem 1991; 266: 43094314.
  • 21
    Goldstein JL, Brown MS. Prevention and treatment of genetic disorders. In: BraunwaldE, IsselbacherKJ, PetersdorfRG, WilsonJD, MartinJB, FauciAS, eds. Principles of Internal Medicine. Volume 1. Ed 11. New York: McGraw–Hill, 1987: 324328.